Omcazio (cabozantinib laurylsulfate)

Where it stands

According to the official record, the US FDA approved Omcazio (cabozantinib laurylsulfate) on 2026-09-03. The sponsor is Handa Oncol, the application is NDA220613, and the dosage form is a capsule. Status is listed as Approved.

The record does not give a therapeutic area or an indication. This analysis therefore cannot say which patients or tumour types the product is approved for, or how it is positioned clinically. The CHMP opinion date is blank ("-"), and the record shows no EU regulatory action for this product. The region is US only.

Regulatory pathway and designations

The only designation listed is "New formulation or manufacturer", which is also how the FDA approval milestone is described. In general, this type of approval covers a changed presentation of an active moiety or a different sponsor or manufacturer. It does not usually imply a new molecular entity. The record does not say which NDA subtype or reference product applies, so any reading beyond the label "new formulation or manufacturer" would be inference.

The record shows no expedited-pathway designations, such as priority review, breakthrough therapy or orphan status. It also has no PDUFA goal date, no review-cycle history and no information on advisory committees or post-marketing requirements. Only the single approval milestone is documented, and it is marked as official.

Safety and pharmacovigilance

The records contain no safety information. They include no label warnings, boxed warning, REMS, adverse-event data, or post-marketing commitments, so none can be assessed here.

Readers should consult the FDA-approved prescribing information for Omcazio for the safety profile and risk-management details. Because this is a new formulation of a named active substance, formulation-specific points such as dosing, administration and any differences from other cabozantinib products should be checked against that label. The records do not address them.

What to watch

The first priority is to obtain the approved label and approval letter for NDA220613. These would confirm the indication, dosing, and whether the capsule is intended to be interchangeable with any existing cabozantinib product. The record does not state any of this.

Other points to follow are the commercial launch timing and any ex-US filings. EU activity would show up as a CHMP opinion, but none is recorded. Any post-marketing commitments or labelling updates published after approval are also worth tracking. The records give no information on these, so they remain open questions rather than expectations.